Anzeige
Mehr »
Login
Sonntag, 25.02.2024 Börsentäglich über 12.000 News von 683 internationalen Medien
Nurexone Biologic: Fallen nächste Woche alle Rekorde?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PSNF | ISIN: US6300873022 | Ticker-Symbol: NV3P
Tradegate
23.02.24
12:39 Uhr
1,140 Euro
-0,090
-7,32 %
Branche
Nanotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NANOVIRICIDES INC Chart 1 Jahr
5-Tage-Chart
NANOVIRICIDES INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,1701,27024.02.
1,1901,26023.02.

Aktuelle News zur NANOVIRICIDES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.02.NANOVIRICIDES, INC. - 8-K, Current Report-
15.02.NanoViricides GAAP EPS of -$0.181
15.02.NanoViricides, Inc.: NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon576SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly...
► Artikel lesen
14.02.NANOVIRICIDES, INC. - 10-Q, Quarterly Report-
01.02.NanoViricides, Inc.: Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics714SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
► Artikel lesen
29.01.NanoViricides reports positive safety results for COVID drug candidate1
29.01.NanoViricides, Inc.: Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found521SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
► Artikel lesen
19.01.NANOVIRICIDES, INC. - 8-K, Current Report2
08.01.NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase 20242
04.01.NanoViricides, Inc.: NanoViricides to Present at the Biotech Showcase in San Fransisco706SHELTON, CT / ACCESSWIRE / January 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
► Artikel lesen
29.11.23NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-3872
28.11.23NanoViricides, Inc.: The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part, Reports NanoViricides884SHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
► Artikel lesen
15.11.23NanoViricides, Inc.: NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications1.032SHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending...
► Artikel lesen
14.11.23NanoViricides, Inc.: Broad-Spectrum Antiviral NV-387 in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development574SHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology...
► Artikel lesen
16.10.23NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV730SHELTON, CT / ACCESSWIRE / October 16, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023...
► Artikel lesen
13.10.23NANOVIRICIDES, INC. - 10-K, Annual Report2
12.10.23NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET643SHELTON, CT / ACCESSWIRE / October 12, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at...
► Artikel lesen
01.09.23NANOVIRICIDES, INC. - 8-K, Current Report2
21.08.23NanoViricides, Inc.: The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides1.099SHELTON, CT / ACCESSWIRE / August 21, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
► Artikel lesen
11.07.23NanoViricides, Inc.: Company's Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides903SHELTON, CT / ACCESSWIRE / July 11, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
► Artikel lesen
Seite:  Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1